Global Plaque Psoriasis Treatment Market To Be Valued US$ 20,388.2 Mn by 2023

17/mag/2018 12:04:36 PBIGP Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.


The Global Plaque Psoriasis Treatment Market poised to reach USD 20,388.2 Million by 2023 with a significant CAGR over the forecast period (2018-2023) owing to increase in prevalence of the psoriasis conditions all across the globe


Precision Business Insights (PBI) in its report titled “Global Plaque Psoriasis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2017 and Forecast 2018-2023” assesses the market performance over six years forecast period. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period.


The global plaque psoriasis treatment market was valued at USD 11,411.7 Million in 2017 and projected to reach USD 20,388.2 Million by 2023 owing to increase in the prevalence of the psoriasis conditions all across the globe. Increase in awareness about the psoriasis conditions and active participation of non-profit organizations to bring awareness among the psoriasis patients about the new therapies are expected to drive the plaque psoriasis market. The novel treatments for plaque psoriasis and the co-pay programs are anticipated to propel the Global plaque psoriasis treatment market. However, high cost of plaque psoriasis treatment products and lack of disease awareness in underdeveloped countries are hinder the growth of global plaque psoriasis treatment market over forecast years.


Free sample of this report is available upon request @


Global Plaque Psoriasis Treatment market segmented on the basis of product type, route of administration, distribution channel, and country

Interleukin Inhibitors accounted for higher revenue share 

Based on product type global plaque psoriasis treatment market segmented into Interleukin Inhibitors, Tumor Necrosis Factor (TNF), and others. Interleukin Inhibitors expected to account a significant revenue share in global plaque psoriasis treatment market with share of 32.4% (2018) in global market and projected to grow at 20.0% CAGR over 2018 and 2023.

North America leads the Global Plaque Psoriasis Treatment market

PBI’s global plaque psoriasis treatment market report analyses the market in different regions such as North America, Europe, and rest of the world. According to regional analysis, The market for plaque psoriasis treatment estimated to be valued at US$ XX Mn in 2018 and poised to grow at 7.9% CAGR over the forecast period (2018 – 2023) owing to growing introduction of biologics in US market.


Free TOC of this report is available upon request @


Licensing agreements, partnerships & collaboration strategic alliances are the key strategies adopted by market players


Global plaque psoriasis treatment market report further reveals that the key players increasingly adopting strategies such as licensing agreements, partnerships & collaboration to improve market revenue share and gaining significant geographic presence across the region. For instance In July 2017, Almirall and Sun Pharma has entered into a license agreement on the development and commercialization of tildrakizumab for psoriasis in Europe. Under terms of the license agreement, Sun Pharma will be eligible to receive development and regulatory milestone payments and, additionally, sales milestone payments and royalties on net sales. Almirall will be able to lead European studies, and participate in larger global clinical studies for psoriasis indication.

Key player’s profiles in the report are Novartis AG (Switzerland), AbbVie Inc. (U.S), Amgen, Inc. (U.S), Johnson & Johnson (U.S), Eli Lilly and Company (U.S), Celgene Corporation (U.S), Sun Pharmaceuticals Industries Ltd. (India)

Need more information about this report @


Detailed Segmentation


By Product Type

·         Interleukin Inhibitors

§  Tildrakizumab

§  Guselkumab

§  Ixekizumab

§  Secukinumab

§  Ustekinumab

§  Brodalumab

·         Tumor Necrosis Factor (TNF)

§  Etanercept

§  Adalimumab

§  Infliximab

·         Others


By Route of Administration

·         Topical

·         Parenteral

·         Others


By Distribution Channel Type

·         Hospital Pharmacies

·         Retail Pharmacies

·         Others



·         North America

§  The U.S

§  Canada

·         Europe

§  Germany

§  France

§  UK

§  Italy

§  Spain

§  Rest of Europe

·         Rest of the world

§  Japan

§  China

§  India

§  Brazil

§  Others


Get access to full summary @


About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX


Toll Free (US):+1-866-598-1553

Website @



blog comments powered by Disqus è un servizio offerto da Factotum Srl